AdrenoMed

2026 Surviving Sepsis Campaign Guidelines and U.S. SEPSIS Act reinforce the need to close persistent therapeutic gaps in septic shock and improve survival through personalized, evidence-based approachesFollowing alignment with regulatory authorities in th

Hennigsdorf / Berlin (Germany), May 19, 2026 (GLOBE NEWSWIRE) -- Press Release

Precision medicine approach: Targeted treatment using two biomarkers (bio-ADM and DPP3) identifies septic shock patients most likely to benefit from enibarcimab treatmentPromising clinical results: Peer-reviewed data show enibarcimab improves organ functi

In this insightful article in The Lancet, editor Jacqueline Duda spoke with our CEO, Richard Jones, and Head of BD, Dr. Martina Kalle-Brune, about the pressing need for innovative strategies to combat sepsis.Read the full article here: Link to article in

J.P. Morgan Week & Biotech Showcase 13 - 16 January San Francisco, California, USA Meet the AdrenoMed team in San Francisco. Link to J.P.Morgan Healthcare Conference Link to Biotech Showcase

AdrenoMed will attend the 2024 World Sepsis Day Symposium on Wednesday, September 11, 2024.On the margins of the 2024 World Sepsis Day, the Global Sepsis Alliance and the European Sepsis Alliance are joining the Sepsis Stiftung in convening an internation

3CT 2024 - Critical Care Clinical Trialists Workshop13-15 June Wahsington DC, USA Vist the 3CT website.

Hennigsdorf/Berlin (Germany), April 10, 2024 -AdrenoMed AG, the vascular integrity company, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-n

Adrenomed AG

With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths worldwideEnibarcimab has the potential to become the first tr